Black Diamond Therapeutics is guided by its executive leadership team, with Master of Science and executive management professionals directing its precision oncology programs. The corporate leadership focuses heavily on discovering and developing novel mutation-selective small molecule therapies designed to treat various forms of genetically driven human cancers by targeting family-specific oncogenic driver mutations while sparing wild-type proteins.